Alzheimer Disease
Alzheimer disease study with Dimebon initiated
Published in Medical Letter on the CDC and FDA, October 16th, 2005
This randomized, double-blinded, placebo-controlled study is being conducted at approximately 12 sites in Russia, and will enroll up to 166 patients. The study's clinical endpoints are the same ones used by the U.S. Food and Drug Administration (FDA) to approve all of the presently marketed Alzheimer's disease drugs. Medivation estimates that patient dosing in this study will be completed by June 30, 2006.
Dimebon has been approved for use in Russia as an antihistamine since 1983. More recently, Dimebon was shown to bind to both...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Environmental Health
Biologic monitoring of exposure to environmental chemicals discussed - Food-Borne Illness
Enrichment procedure for E. coli compared with standard methods - Glucose Monitoring
Accuracy of glucose monitors with different specimen matrices assessed - Pertussis Vaccine
Efficacy of pertussis vaccine in U.S. children examined - Adolescent Health
Fighting attributed to alcohol use among adolescent drinkers - Anthrax Vaccine Development
Antibody patterns in anthrax vaccinees reported - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
